Liquidia Corporation (LQDA) Has 50%+ Upside on Yutrepia Ruling and Buyout Potential

1 month ago 32

Soumya Eswaran

Tue, July 28, 2026 astatine 7:44 AM CDT 3 min read

Buckley Capital Advisors, an concern absorption company, released its 2nd 4th 2026 capitalist letter. A transcript of the missive tin be downloaded here. The 2nd 4th delivered strong, broad-based gains crossed the portfolio, with respective of the Fund's largest positions contributing to performance. Buckley Capital returned 36.0% nett during the 4th and 29.7% nett year-to-date, outperforming the iShares Russell 2000 Value and iShares Russell 2000. The steadfast remained disciplined successful recycling superior by trimming oregon exiting investments wherever the thesis had played retired oregon the risk-reward had weakened. Capital was redirected toward businesses wherever improving fundamentals, catalysts, and charismatic valuations enactment semipermanent upside. The steadfast continues to absorption connected misunderstood tiny and mid-cap companies with underappreciated net powerfulness and believes the portfolio is among its strongest successful caller years. In addition, delight cheque the firm's apical 5 holdings to cognize its champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Buckley Capital highlighted Liquidia Corporation (NASDAQ:LQDA). Liquidia Corporation (NASDAQ:LQDA) is simply a biopharmaceutical company, focusing connected processing therapies for uncommon cardiopulmonary diseases. On July 27, 2026, Liquidia Corporation (NASDAQ:LQDA) closed astatine $84.42 per share. One-month instrumentality of Liquidia Corporation (NASDAQ:LQDA) was 5.88% and its shares gained 338.32% implicit the past 52 weeks. Liquidia Corporation (NASDAQ:LQDA) has a marketplace capitalization of $7.50 billion.

Buckley Capital stated the pursuing regarding Liquidia Corporation (NASDAQ:LQDA) in its Q2 2026 capitalist letter:

"Liquidia Corporation (NASDAQ:LQDA) continues to beryllium the acquisition that keeps connected giving. At our mean cost, we bought LQDA astatine astir 1.5x our estimates for 2027 net and ~1x 2028 earnings. We primitively purchased LQDA astatine $5.00/share; our mean outgo is astir $9.00, and contiguous the shares commercialized astatine astir $78. We person continually adjusted our delta-adjusted presumption size utilizing options arsenic a hazard absorption tool, but LQDA has inactive been our largest contributor YTD, up implicit 100% truthful acold this year.

We are inactive waiting connected Judge Andrews' determination connected whether LQDA volition beryllium capable to merchantability its Yutrepia merchandise for PH-ILD (pulmonary hypertension associated with interstitial lung disease), a ruling that is apt to hap sometime soon. Despite the stock's appreciation, we inactive consciousness determination is 50%+ upside to what an acquirer would wage for the concern today. We judge Andrews volition regularisation successful LQDA's favor, and that an acquirer is apt to travel successful soon aft the ruling."

Read Entire Article